Securitize partners with LG CNS to develop tokenized asset infrastructure in South Korea

Bitget2026/10/06 13:03

Securitize entered a strategic partnership with South Korea’s LG CNS to develop tokenized assets and digital asset infrastructure for Korean financial institutions. Collaboration targets tokenized funds, equities, stablecoins, broader onchain financial products, with joint go-to-market work across Korea and Asia-Pacific. Work includes tailoring tokenization solutions to Korea’s evolving regulatory framework, with an aim to support 24/7 distribution, execution, settlement. Partnership also evaluates stablecoin infrastructure, digital asset treasury solutions, potential links between Korean and global markets, subject to approvals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Securitize Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: FL64517) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Citi: French fiscal risks may cause ECB to pause rate hikes after December, euro likely to drop below 1.10

华尔街见闻•2026/10/10 07:43

Morgan Stanley raises CME Group price target to $337

格隆汇•2026/10/10 07:37

Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Chaincatcher•2026/10/10 07:19

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21